Nektar Therapeutics (NKTR) Misses Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $72.67 --0%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
HSAI, SYRS, EGRX, More
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
HSAI, SYRS, EGRX, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.36), $0.03 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $32.77 million versus the consensus estimate of $30.47 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Klarna shares tumble on weak full-year revenue guidance
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Noble Capital Starts Xerox (XRX) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
